Literature DB >> 29056151

The Role of Neuropeptide Y (NPY) in Alcohol and Drug Abuse Disorders.

Stacey L Robinson1, Todd E Thiele2.   

Abstract

Neuropeptide Y (NPY) is a neuromodulator that is widely expressed throughout the central nervous system (CNS) and which is cosecreted with classic neurotransmitters including GABA and glutamate. There is a long history of research implicating a role for NPY in modulating neurobiological responses to alcohol (ethanol) as well as other drugs of abuse. Both ethanol exposure and withdrawal from chronic ethanol have been shown to produce changes in NPY and NPY receptor protein levels and mRNA expression in the CNS. Importantly, manipulations of NPY Y1 and Y2 receptor signaling have been shown to alter ethanol consumption and self-administration in a brain region-specific manner, with Y1 receptor activation and Y2 receptor blockade in regions of the extended amygdala promoting robust reductions of ethanol intake. Similar observations have been made in studies examining neurobiological responses to nicotine, psychostimulants, and opioids. When taken together with observations of potential genetic linkage between the NPY system and the human alcohol abuse disorders, NPY represents a promising target for treating problematic alcohol and drug use, and in protecting individuals from relapse during abstinence.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcoholism; Binge; Consumption; Dependence; Ethanol; Neuropeptide Y; Relapse; Y1 receptor; Y2 receptor; Y5 receptor

Mesh:

Substances:

Year:  2017        PMID: 29056151     DOI: 10.1016/bs.irn.2017.06.005

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  24 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 2.  Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions.

Authors:  Pravin Shende; Drashti Desai
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Transcriptional Regulators as Targets for Alcohol Pharmacotherapies.

Authors:  Antonia M Savarese; Amy W Lasek
Journal:  Handb Exp Pharmacol       Date:  2018

4.  PACAP and Other Neuropeptide Targets Link Chronic Migraine and Opioid-induced Hyperalgesia in Mouse Models.

Authors:  Krishna D. B. Anapindi; Ning Yang; Elena V Romanova; Stanislav S Rubakhin; Alycia Tipton; Isaac Dripps; Zoie Sheets; Jonathan V Sweedler; Amynah A Pradhan
Journal:  Mol Cell Proteomics       Date:  2019-10-24       Impact factor: 5.911

5.  Identifying roles for peptidergic signaling in mice.

Authors:  Kathryn G Powers; Xin-Ming Ma; Betty A Eipper; Richard E Mains
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-27       Impact factor: 11.205

Review 6.  Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics.

Authors:  Yan Zhou; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2018-04-18       Impact factor: 4.030

Review 7.  Behavioral, neurobiological, and neurochemical mechanisms of ethanol self-administration: A translational review.

Authors:  Ashley A Vena; Shannon L Zandy; Roberto U Cofresí; Rueben A Gonzales
Journal:  Pharmacol Ther       Date:  2020-05-11       Impact factor: 12.310

8.  Medial prefrontal cortex neuropeptide Y modulates binge-like ethanol consumption in C57BL/6J mice.

Authors:  Stacey L Robinson; Isabel M Marrero; Carlos A Perez-Heydrich; Marian T Sepulveda-Orengo; Kathryn J Reissner; Todd E Thiele
Journal:  Neuropsychopharmacology       Date:  2019-01-07       Impact factor: 7.853

9.  Cell-type specific knockout of peptidylglycine α-amidating monooxygenase reveals specific behavioral roles in excitatory forebrain neurons and cardiomyocytes.

Authors:  Kathryn G Powers; Xin-Ming Ma; Betty A Eipper; Richard E Mains
Journal:  Genes Brain Behav       Date:  2020-09-24       Impact factor: 3.449

10.  CB1 receptor neutral antagonist treatment epigenetically increases neuropeptide Y expression and decreases alcohol drinking.

Authors:  Russell S Dulman; Huaibo Zhang; Ritabrata Banerjee; Harish R Krishnan; Bin Dong; Basalingappa L Hungund; K Yaragudri Vinod; Subhash C Pandey
Journal:  Neuropharmacology       Date:  2021-05-26       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.